行业分析 |
|
|
|
|
基因治疗产品的开发现状与挑战 |
徐应永() |
再鼎医药(上海)有限公司 上海 201210 |
|
Current Status and Challenges of Gene Therapy Products |
XU Ying-yong() |
Zai Lab (Shanghai) Co., Ltd,Shanghai 201210,China |
[1] |
High K A, Roncarolo M G. Gene therapy. The New England Journal of Medicine, 2019,381(5):455-464.
doi: 10.1056/NEJMra1706910
pmid: 31365802
|
[2] |
Dunbar C E, High K A, Joung J K, et al. Gene therapy comes of age. Science, 2018, 359(6372):eaan4672.
pmid: 29326257
|
[3] |
Wirth T, Parker N, Yla-Herttuala S. History of gene therapy. Gene, 2013,525(2):162-169.
doi: 10.1016/j.gene.2013.03.137
pmid: 23618815
|
[4] |
Steffin D H M, Hsieh E M, Rouce R H. Gene therapy: Current applications and future possibilities. Advances in Pediatrics, 2019,66:37-54.
pmid: 31230699
|
[5] |
Mukherjee S. The gene: An intimate history. New York: Scribner, 2016.
|
[6] |
迟培娟, 王学昭, 陈芳, 等. 基因治疗及细胞治疗发展态势分析. 中国生物工程杂志, 2019,39(5):43-52.
|
|
Chi P J, Wang X Z, Chen F, et al. The analysis of development trend for gene and cell therapy. China Biotechnology, 2019,39(5):43-52.
|
[7] |
Zhang W W, Li L, Li D, et al. The first approved gene therapy product for cancer Ad-p53 (Gendicine): 12 years in the clinic. Human Gene Therapy, 2018,29(2):160-179.
pmid: 29338444
|
[8] |
Xin H. Chinese gene therapy. Gendicine’s efficacy: hard to translate. Science, 2006,314(5803):1233.
doi: 10.1126/science.314.5803.1233
pmid: 17124301
|
[9] |
Melchiorri D, Pani L, Gasparini P, et al. Regulatory evaluation of Glybera in Europe - two committees, one mission. Nature Reviews Drug Discovery, 2013,12(9):719.
doi: 10.1038/nrd3835-c1
pmid: 23954897
|
[10] |
Bryant L M, Christopher D M, Giles A R, et al. Lessons learned from the clinical development and market authorization of Glybera. Hum Gene Ther Clin Dev, 2013,24(2):55-64.
pmid: 23808604
|
[11] |
Senior M. After Glybera’s withdrawal, what’s next for gene therapy? Nat Biotechnol, 2017,35(6):491-492.
doi: 10.1038/nbt0617-491
pmid: 28591128
|
[12] |
Greig S L. Talimogene Laherparepvec: First global approval. Drugs, 2016,76(1):147-154.
pmid: 26620366
|
[13] |
Cicalese M P, Ferrua F, Castagnaro L, et al. Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency. Blood, 2016,128(1):45-54.
pmid: 27129325
|
[14] |
Maude S L, Laetsch T W, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. The New England Journal of Medicine, 2018,378(5):439-448.
pmid: 29385370
|
[15] |
Neelapu S S, Locke F L, Bartlett N L, et al. Axicabtagene Ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. The New England Journal of Medicine, 2017,377(26):2531-2544.
doi: 10.1056/NEJMoa1707447
pmid: 29226797
|
[16] |
Ameri H. Prospect of retinal gene therapy following commercialization of voretigene neparvovec-rzyl for retinal dystrophy mediated by RPE65 mutation. Journal of Current Ophthalmology, 2018,30(1):1-2.
pmid: 29564403
|
[17] |
Russell S, Bennett J, Wellman J A, et al. Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: A randomised, controlled, open-label, phase 3 trial. Lancet, 2017,390(10097):849-860.
doi: 10.1016/S0140-6736(17)31868-8
pmid: 28712537
|
[18] |
Thompson A A, Walters M C, Kwiatkowski J, et al. Gene therapy in patients with transfusion-dependent beta-thalassemia. The New England Journal of Medicine, 2018,378(16):1479-1493.
doi: 10.1056/NEJMoa1705342
|
[19] |
Hoy S M. Onasemnogene Abeparvovec: First global approval. Drugs, 2019,79(11):1255-1262.
doi: 10.1007/s40265-019-01162-5
pmid: 31270752
|
[20] |
Goswami R, Subramanian G, Silayeva L, et al. Gene Therapy leaves a vicious cycle. Frontiers in Oncology, 2019,9:297.
doi: 10.3389/fonc.2019.00297
pmid: 31069169
|
[21] |
Peyvandi F, Garagiola I, Young G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet, 2016,388(10040):187-197.
doi: 10.1016/S0140-6736(15)01123-X
pmid: 26897598
|
[22] |
Rangarajan S, Walsh L, Lester W, et al. AAV5-factor VIII gene transfer in severe hemophilia A. The New England Journal of Medicine, 2017,377(26):2519-2530.
doi: 10.1056/NEJMoa1708483
pmid: 29224506
|
[23] |
Bender E. Gene therapy: Industrial strength. Nature, 2016,537(7619):S57-59.
doi: 10.1038/537S57a
pmid: 27602741
|
[24] |
Wang D, Tai P W L, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nature Reviews Drug Discovery, 2019,18(5):358-378.
doi: 10.1038/s41573-019-0012-9
pmid: 30710128
|
[25] |
Brenner M K, Stephen G, Leen A M, et al. Is cancer gene therapy an empty suit? Lancet Oncology, 2013,14(11):e447-e456.
doi: 10.1016/S1470-2045(13)70173-6
pmid: 24079872
|
[26] |
Xu L, Wang J, Liu Y, et al. CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia. New England Journal of Medicine, 2019,381(13):1240-1247.
|
[27] |
Sun J, Zhao Y, Yang R, et al. The demographics, treatment characteristics and quality of life of adult people with haemophilia in China - results from the HERO study. Haemophilia, 2017,23(1):89-97.
doi: 10.1111/hae.13071
pmid: 27599642
|
[28] |
Brennan T A, Wilson J M. The special case of gene therapy pricing. Nature Biotechnology, 2014,32(9):874-876.
doi: 10.1038/nbt.3003
pmid: 25203033
|
[29] |
Seppo Y H. Glybera’s second act: the curtain rises on the high cost of therapy. Molecular Therapy, 2015,23(2):217-218.
doi: 10.1038/mt.2014.248
pmid: 25633169
|
[30] |
Nicolas T, Mathias F. The payers’ perspective on gene therapies. Nature Biotechnology, 2015,33(9):902-904.
doi: 10.1038/nbt.3332
pmid: 26348952
|
[31] |
Machin N, Ragni M V, Smith K J. Gene therapy in hemophilia A: a cost-effectiveness analysis. Blood Advances, 2018,2(14):1792-1798.
doi: 10.1182/bloodadvances.2018021345
pmid: 30042145
|
[32] |
Mohamed A E E, Gerhard B, Petra R. The business case for cell and gene therapies. Nature Biotechnology, 2014,32(12):1192-1193.
doi: 10.1038/nbt.3084
pmid: 25489833
|
[33] |
Schimmer J, Breazzano S. Investor outlook: Solving gene therapy pricing…with a cures voucher? Human Gene Therapy Clinical Development, 2016,27(4):132-136.
doi: 10.1089/humc.2016.29018.ind
pmid: 27983892
|
[34] |
Collins F S, Gottlieb S. The next phase of human gene-therapy oversight. The New England Journal of Medicine, 2018,379(15):1393-1395.
doi: 10.1056/NEJMp1810628
pmid: 30110242
|
[35] |
Kenter M J H. Is it time to reform oversight of clinical gene therapy in the EU? British Journal of Clinical Pharmacology, 2019,85(1):8-10.
doi: 10.1111/bcp.13795
pmid: 30341921
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|